NASDAQ · CRMD

CorMedix Inc.

Healthcare · Biotechnology

$7.79▼ 0.38% ($0.03)at close

As of 4:00 PM ET

52-week

$6.13$13.02

Market cap

$611.14M

P/E

3.85

EPS (TTM)

$2.02

Next earnings

Nov 11, 2026

What the market price implies · Reverse DCF

To support a price of $7.79, this model requires revenue to grow by -2.51%/yr over the next 10 years, compounded annually.

Historical revenue grew by 535.65%/yr over the past 4 years. The required annual growth rate is 538.16 percentage points lower.

Selected forecast · Base scenario

19.61%/yr · actual 10-year annualized revenue growth

Year 1 growth: 40%

Market-implied · Base operating assumptions + edited margins

-2.51%/yr · flat 10-year annualized revenue growth

Reverse DCF solves revenue growth itself using Base operating assumptions and your edited margins. Changing forecast growth alone does not change the implied rate. This is a model-implied requirement, not an analyst forecast.

Valuation

Recommended · Revenue & margin DCF

Price used

$7.79

Estimated value / share

$231.08

Base scenario

This estimate is 2,866.37% above the price used.

USD · TTM ending 2026-06-30

Only 4 of the five annual revenue periods are available; growth uses the observed fiscal-year spans. Annual revenue history contains a gap; multi-year changes are annualized over their actual fiscal-year span. Latest quarterly growth differs materially from the latest annual pace. It remains an observed growth input; review whether acceleration or a change in the business explains it.

This estimate is at least 3× the price used. Review the growth, margin and investment assumptions behind the gap.

Year 1 growth 40% · Ending margin 30% · Discount rate 11.5%

Assumption scenarios, not statistical confidence intervals.

Method, dates & sources

Estimated from future revenue, operating margins, and the investment needed to support them.

Price timestamp: Sep 17, 2026, 8:00 PM UTC
Financial statement period: TTM ending 2026-06-30
Data refreshed: Sep 18, 2026, 4:13 AM UTC · provider

Why this method?

There is not a stable run of positive FCFF to anchor a direct cash-flow CAGR, so the model should start from revenue and margin assumptions instead.

Is FCFF positive and has it been for 3+ consecutive years? Only 1 consecutive positive FCFF years are available.

Price vs Fundamentals

Why The Stock Is Moving

Likely multiple compressionModerate confidence

1Y Price: -29.95%Revenue (TTM): 280.5%FCF (TTM): 727.72%P/S: 0th pct

What changed

The stock fell 29.95% over the last year. Revenue grew 280.5% over the trailing twelve months. Operating margin moved from 40.6% to 46.95%. Free cash flow grew 727.72% over the trailing twelve months.

What the market seems to be pricing

Visible fundamentals weakened far less than the stock price. The market appears to be discounting durability, risk, or trust rather than just the latest reported numbers.

What would invalidate this read

This read changes if operating margin (currently 46.95%) continues to decline, or if revenue growth turns negative. The bull case requires the business to hold its current trajectory.

Performance

Return analysis

Company profile

CorMedix Inc. is a biopharmaceutical company engaged in the development and commercialization of medical treatments for the prevention and care of infectious and inflammatory conditions, serving markets both in the United States and internationally.

CEOJoseph Todisco

SectorHealthcare

IndustryBiotechnology

Employees191

IPO dateMay 13, 2010

https://www.cormedix.com

Market multiples

Forward P/E—

EV/EBITDA5.01

Enterprise value$840.84M

Stock splits

Mar 26, 2019↓ Reverse

Every 5 shares became 1

-80%

Profitability & growth

Revenue growth156.52%

Gross margin (FY2025)88.46%▼4.2ppvs FY2024

Operating margin (FY2025)48.17%▲99.6ppvs FY2024

ROE54.93%▼11.6ppvs FY2025

Analyst consensus

RatingBuy

Target price$14.00▲79.72%

Buy

Hold

Sell

Analyst ratings tend to be lagging indicators. Use as one signal among many.

Earnings

Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.

Next report

Nov 11, 2026

Q4 FY26 · EPS est -$0.10 · Revenue est $53.27M

View

NASDAQ · CRMD

CorMedix Inc.

Healthcare · Biotechnology

$7.79▼ 0.38% ($0.03)at close

As of 4:00 PM ET

52-week

$6.13$13.02

Market cap

$611.14M

P/E

3.85

EPS (TTM)

$2.02

Next earnings

Nov 11, 2026

What the market price implies · Reverse DCF

To support a price of $7.79, this model requires revenue to grow by -2.51%/yr over the next 10 years, compounded annually.

Historical revenue grew by 535.65%/yr over the past 4 years. The required annual growth rate is 538.16 percentage points lower.

Selected forecast · Base scenario

19.61%/yr · actual 10-year annualized revenue growth

Year 1 growth: 40%

Market-implied · Base operating assumptions + edited margins

-2.51%/yr · flat 10-year annualized revenue growth

Valuation

Recommended · Revenue & margin DCF

Price used

$7.79

Estimated value / share

$231.08

Base scenario

This estimate is 2,866.37% above the price used.

USD · TTM ending 2026-06-30

This estimate is at least 3× the price used. Review the growth, margin and investment assumptions behind the gap.

Year 1 growth 40% · Ending margin 30% · Discount rate 11.5%

Assumption scenarios, not statistical confidence intervals.

Method, dates & sources

Estimated from future revenue, operating margins, and the investment needed to support them.

Price timestamp: Sep 17, 2026, 8:00 PM UTC
Financial statement period: TTM ending 2026-06-30
Data refreshed: Sep 18, 2026, 4:13 AM UTC · provider

Why this method?

There is not a stable run of positive FCFF to anchor a direct cash-flow CAGR, so the model should start from revenue and margin assumptions instead.

Is FCFF positive and has it been for 3+ consecutive years? Only 1 consecutive positive FCFF years are available.

Price vs Fundamentals

Why The Stock Is Moving

Likely multiple compressionModerate confidence

1Y Price: -29.95%Revenue (TTM): 280.5%FCF (TTM): 727.72%P/S: 0th pct

What changed

What the market seems to be pricing

Visible fundamentals weakened far less than the stock price. The market appears to be discounting durability, risk, or trust rather than just the latest reported numbers.

What would invalidate this read

This read changes if operating margin (currently 46.95%) continues to decline, or if revenue growth turns negative. The bull case requires the business to hold its current trajectory.

Performance

Return analysis

Company profile

CEOJoseph Todisco

SectorHealthcare

IndustryBiotechnology

Employees191

IPO dateMay 13, 2010

https://www.cormedix.com

Market multiples

Forward P/E—

EV/EBITDA5.01

Enterprise value$840.84M

Stock splits

Mar 26, 2019↓ Reverse

Every 5 shares became 1

-80%

Profitability & growth

Revenue growth156.52%

Gross margin (FY2025)88.46%▼4.2ppvs FY2024

Operating margin (FY2025)48.17%▲99.6ppvs FY2024

ROE54.93%▼11.6ppvs FY2025

Analyst consensus

RatingBuy

Target price$14.00▲79.72%

Buy

Hold

Sell

Analyst ratings tend to be lagging indicators. Use as one signal among many.

Earnings

Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.

Next report

Nov 11, 2026

Q4 FY26 · EPS est -$0.10 · Revenue est $53.27M

View